Puma Biotechnology reported $63.13M in Cash and Equivalent for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US $ 203.13M 197.1M
Bluebird Bio BLUE:US $ 396.62M 5.84M
Cerulean Pharma CERU:US $ 51.67M 6.1M
Daiichi Sankyo 4568:JP Y 577295M 27241M
Mirati Therapeutics MRTX:US $ 293.42M 100.32M
Novartis NOVN:VX SF 12407M 5196M
Sangamo Biosciences SGMO:US $ 120.26M 58.62M
Spectrum Pharmaceuticals SPPI:US $ 78.68M 9.86M
Tg Therapeutics TGTX:US $ 298.89M 27.62M